Oral Mucositis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Oral Mucositis - Pipeline Review, H2 2016

Oral Mucositis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Oral Mucositis - Pipeline Review, H2 2016
Published Aug 17, 2016
90 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Oral Mucositis - Pipeline Review, H2 2016, provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
- The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop an

  
Source:
Document ID
GMDHC8372IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Oral Mucositis Overview81
Therapeutics Development92
  Pipeline Products for Oral Mucositis Overview91
  Pipeline Products for Oral Mucositis Comparative Analysis101
Oral Mucositis Therapeutics under Development by Companies111
Oral Mucositis Therapeutics under Investigation by Universities/Institutes121
Oral Mucositis Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Oral Mucositis Products under Development by Companies161
Oral Mucositis Products under Investigation by Universities/Institutes171
Oral Mucositis Companies Involved in Therapeutics Development1811
  Aldeyra Therapeutics, Inc.181
  Cellceutix Corporation191
  Colby Pharmaceutical Company201
  Daewoong Pharmaceutical Co., Ltd.211
  Galera Therapeutics, Inc.221
  Onxeo SA231
  Oragenics, Inc.241
  Otsuka Holdings Co., Ltd.251
  Soligenix, Inc.261
  Spectrum Pharmaceuticals, Inc.271
  Spherium Biomed S.L.281
Oral Mucositis Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3837
  AG-013 Drug Profile382
  brilacidin tetrahydrochloride Drug Profile409
  clonidine hydrochloride ER Drug Profile493
  dusquetide Drug Profile524
  GC-4419 Drug Profile562
  Gene Therapy for Oral Mucositis Drug Profile581
  Gene Therapy for Oral Mucositis Drug Profile591
  KIN-219 Drug Profile601
  nepidermin Drug Profile611
  NS-2 Drug Profile623
  pralatrexate Drug Profile656
  rebamipide Drug Profile712
  Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders Drug Profile731
  SP-13004 Drug Profile741
Oral Mucositis Dormant Projects753
Oral Mucositis Discontinued Products781
Oral Mucositis Product Development Milestones7910
  Featured News &Press Releases791
    Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis791
    Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference791
    Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis801
    May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol811
    Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide811
    Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis821
    Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis831
    Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients832
    Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015851
    Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis851
    Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis851
    Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015861
    Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting871
    Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients871
    Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis881
Appendix892
  Methodology891
  Coverage891
  Secondary Research891
  Primary Research891
  Expert Panel Validation891
  Contact Us891
  Disclaimer901

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Oral Mucositis - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Oral-Mucositis-Pipeline-Review-H2-2016-2088-16398>
  
APA:
Global Markets Direct - Market Research. (2016). Oral Mucositis - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Oral-Mucositis-Pipeline-Review-H2-2016-2088-16398>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.